April 23, 2018, Chongqing, China and Redwood City, Calif.–Porton Pharma Solutions, Ltd.(SZSE: 300363, “Porton”) and Codexis, Inc.(NASDAQ: CDXS, “Codexis”) announce a strategic collaboration to deploy Codexis’world-leading biocatalyst technology within Porton’s global custom intermediateand active pharmaceutical ingredients (API) development and manufacturing business. The partnership will accelerate the creation and commercialization of new, low-cost, sustainable manufacturing processes, exploiting the benefits of biocatalysts to a growing number of the world’s small molecule pharmaceuticals.

“We are delighted to establish this unique partnership with Porton,” said John Nicols, president and CEO of Codexis. “Given Porton’s significant and fast-growing presence as a leading global CDMO, we will now be able to reach a greater share of the world’s pharmaceutical manufacturing market.”

About Codexis

Codexis is a leading protein engineering company that applies its proprietary CodeEvolver® technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics. Codexis’ proven technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes. For more information, see www.codexis.com.

Codexis Contacts: